Cellis is developing Macrophage Drug Conjugates (MDCs) which is a breakthrough, new class of therapy for solid tumors. Cellis uses allogeneic macrophages conjugated with therapeutic medications for treatment of several solid tumors. Our focus is on glioblastoma, ovarian and pancreatic cancer.
Some insights
Cellis is developing new breakthrough therapy of solid tumors, based on the biological mechanisms involving macrophages and cancer cells interactions.